AbbVie Inc

• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.

• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.

• Ascendis Pharma stock fell after terminating its collaboration agreement with Novo Nordisk. • Investors worry about independent funding and high expenses for obesity clinical programs. • The company reported an annual revenue of $854.80M and net loss.

• Eli Lilly management highlighted core metabolic therapies and late-stage pipeline updates. • The company reported $65.18 billion in annual revenue and strong net profits. • Analysts maintain Buy ratings with an average price target of $1300.31.

• AbbVie successfully completed a multi-billion dollar debt offering to fund the Apogee acquisition. • Second-quarter revenue expanded by double digits, prompting an upgrade to full-year guidance. • Analysts issued Buy ratings with an average price target of $276.42.

• Vertex reported positive Phase 3 data for its non-opioid pain treatment candidate. • The company raised its full-year revenue guidance following successful international product launches. • Analysts maintain a Buy rating with an average price target of $557.64.